Results 161 to 170 of about 144,049 (286)

The Utility of Intranasal Corticosteroids in Association With Dupilumab for Chronic Rhinosinusitis With Nasal Polyposis: A Real‐Life Multicenter Study by a Tuscany Group

open access: yesWorld Journal of Otorhinolaryngology - Head and Neck Surgery, EarlyView.
ABSTRACT Objective Chronic rhinosinusitis with nasal polyps (CRSwNP) is a persistent inflammatory condition often associated with other type‐2 diseases. Dupilumab, a monoclonal antibody targeting IL‐4Rα, has revolutionized the treatment of severe CRSwNP.
Pietro Orlando   +17 more
wiley   +1 more source

Distinct Nasal Microbiome Profiles and Prediction Model for Allergic Rhinitis, Nonallergic Rhinitis, and Healthy Children

open access: yesWorld Journal of Otorhinolaryngology - Head and Neck Surgery, EarlyView.
The alpha and beta diversity of the nasal microbiome differed among children with allergic rhinitis (AR), nonallergic rhinitis (NAR), and healthy controls (HCs). Compared to HC, AR had more Escherichia‐Shigella, Negativicoccus, and Campylobacter, while NAR had more Dolosigranulum and fewer Enterobacteriaceae.
Kantima Kanchanapoomi   +6 more
wiley   +1 more source

Breast milk miRNAs and their potential role in the development of atopy in infants. [PDF]

open access: yesFront Mol Biosci
Porębska A   +4 more
europepmc   +1 more source

Inflammatory Shift in Chronic Rhinosinusitis Amidst Guangzhou's Urbanization (2000–2018)

open access: yesWorld Journal of Otorhinolaryngology - Head and Neck Surgery, EarlyView.
ABSTRACT Background Chronic rhinosinusitis (CRS) exhibits temporal and geographic diversity in pathological endotypes with progressive eosinophilic infiltration, while the underlying causes remain unclear. Current pathological endotypes determination relies on mean cell count per high‐power field, requiring accuracy optimization.
Ning Kang   +16 more
wiley   +1 more source

Tapinarof as a Therapeutic Aryl Hydrocarbon Receptor‐Modulating Agent in the Treatment of Atopic Dermatitis

open access: yesThe Journal of Dermatology, EarlyView.
ABSTRACT Atopic dermatitis (AD) is a chronic inflammatory dermatitis underpinned by Type 2 inflammation driven by cytokines such as IL‐4 and IL‐13. It is characterized by skin barrier dysfunction, Th2 immune deviation, and pruritus. While biologics and oral Janus kinase (JAK) inhibitors demonstrate high therapeutic efficacy by targeting cytokines that ...
Gaku Tsuji   +7 more
wiley   +1 more source

Targeted Systemic Therapies for Atopic Dermatitis in Australia: A Narrative Review

open access: yesAustralasian Journal of Dermatology, EarlyView.
ABSTRACT Atopic dermatitis (AD) is a chronic relapsing inflammatory skin disease estimated to affect approximately 30% of children and 10%–15% of adults in Australia. Of those with this condition, one in five is estimated to have moderate‐to‐severe disease.
Diana Rubel   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy